Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1574866
PUBLISHER: Grand View Research | PRODUCT CODE: 1574866
Congestive Heart Failure Drugs Market Size, Share & Trends Analysis Report By Drug (ACE Inhibitors, Angiotensin 2 Receptor Blockers), By Product (Injection, Capsule and Tablets), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Congestive Heart Failure Drugs Market Growth & Trends:
The global Congestive Heart Failure drugs market size is expected to reach USD 19.85 billion in 2030 and is projected to grow at a CAGR of 14.6% from 2024 to 2030. The increase in the prevalence of congestive heart failure (CHF), the rising aging population leading to increased risk of disease, and growing research and development for better treatment approaches are the key factors augmenting the growth. In 2020, around 64.34 million people worldwide were suffering from heart failure. In addition, its estimated prevalence rate is high in patients with diseases such as diabetes and hypertension.
Increasing research and development for better treatment options is a major factor behind the presence of multiple products in the pipeline. Novo Nordisk's Semaglutide, Zensun's Neucardin, Bayer's vericiguat, and AstraZeneca's AZD4831 are among the prominent drug candidates. Moreover, approval of an extended label for sodium-glucose co-transporter 2 (SGLT2) inhibitors for CHF is expected to fuel market growth. For instance, in February 2022, Jardiance (empagliflozin) and in May 2020, Farxiga (dapagliflozin) received label expansion for the treatment of CHF.
Key players such as AstraZeneca; Bristol-Myers Squibb Company; Amgen Inc.; and Boehringer Ingelheim are strategically engaged in geographical expansions, regulatory approvals, collaborations, and partnerships through mergers and acquisitions in emerging and economically favorable regions. For instance, in February 2021, AstraZeneca announced the approval of Forxiga (dapagliflozin) in China, indicated for CHF with or without type-2 diabetes. Before China, the drug was already approved in the U.S., Europe, and Japan for the same indication.
COVID-19 impacted the demand and supply of drugs, and patients faced difficulty in healthcare access, resulting in a decline in product demand amid the pandemic. Due to imposed restrictions, research and development saw a setback in clinical trial proceedings. However, after the pandemic, the industry regained its pace.
Congestive Heart Failure Drugs Market Report Highlights:
- In 2021, the ACE inhibitors segment held the largest share due to its high prescription rate and market penetration
- By drug class, the others segment is expected to be the fastest-growing segment over the forecast period due to the launch of sodium-glucose co-transporter 2 (SGLT2) inhibitors
- By distribution channel, the retail pharmacies segment is expected to witness lucrative growth over the forecast period due to its high compatibility with home care settings and prescription drugs
- North America congestive heart failure drugs market held the largest share of 37.6% in 2023. This can be attributed to the presence of key players, favorable funding assistance, and increased patient awareness
Product Code: GVR-4-68039-987-5
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Congestive Heart Failure Drugs Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
- 3.4. Congestive Heart Failure Drugs Market Analysis Tools
- 3.4.1. Porter's Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
- 3.4.1. Porter's Analysis
Chapter 4. Congestive Heart Failure Drugs Market: Drug Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Congestive Heart Failure Drugs Market: Drug Movement Analysis, USD Million, 2023 & 2030
- 4.3. ACE Inhibitors
- 4.3.1. ACE Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4. Angiotensin 2 Receptor Blockers
- 4.4.1. Angiotensin 2 Receptor Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. Beta Blockers
- 4.5.1. Beta Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Diuretics
- 4.6.1. Diuretics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.7. Aldosterone antagonists
- 4.7.1. Aldosterone antagonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.8. Inotropes
- 4.8.1. Inotropes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.9. Others
- 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Congestive Heart Failure Drugs Market: Product Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Congestive Heart Failure Drugs Market: Product Movement Analysis, USD Million, 2023 & 2030
- 5.3. Injection
- 5.3.1. Injection Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4. Capsule
- 5.4.1. Capsule Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Tablets
- 5.5.1. Tablets Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Congestive Heart Failure Drugs Market: Distribution Channel Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Congestive Heart Failure Drugs Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
- 6.3. Hospitals
- 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4. Retail Pharmacies
- 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Online Pharmacies
- 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Congestive Heart Failure Drugs Market: Regional Estimates & Trend Analysis
- 7.1. Congestive Heart Failure Drugs Market Share, By Region, 2023 & 2030, USD Million
- 7.2. North America
- 7.2.1. North America Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
- 7.2.2.1. U.S. Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
- 7.2.3.1. Canada Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
- 7.2.4.1. Mexico Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3. Europe
- 7.3.1. Europe Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. UK
- 7.3.2.1. UK Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
- 7.3.3.1. Germany Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
- 7.3.4.1. France Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5. Italy
- 7.3.5.1. Italy Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6. Spain
- 7.3.6.1. Spain Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
- 7.3.7.1. Denmark Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
- 7.3.8.1. Sweden Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9. Norway
- 7.3.9.1. Norway Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. China
- 7.4.2.1. China Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Japan
- 7.4.3.1. Japan Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
- 7.4.4.1. India Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. South Korea
- 7.4.5.1. South Korea Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. Australia
- 7.4.6.1. Australia Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
- 7.4.7.1. Thailand Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
- 7.5.2.1. Brazil Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Argentina
- 7.5.3.1. Argentina Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. South Africa
- 7.6.2.1. South Africa Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Saudi Arabia
- 7.6.3.1. Saudi Arabia Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. UAE
- 7.6.4.1. UAE Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
- 7.6.5.1. Kuwait Congestive Heart Failure Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis by Key Market Participants
- 8.2. Company Categorization
- 8.3. Company Heat Map Analysis
- 8.4. Company Profiles
- 8.4.1. Bayer AG
- 8.4.1.1. Participant's Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. Novartis AG
- 8.4.2.1. Participant's Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. Merck & Co., Inc.
- 8.4.3.1. Participant's Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. AstraZeneca
- 8.4.4.1. Participant's Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Bristol-Myers Squibb Company
- 8.4.5.1. Participant's Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. Amgen Inc.
- 8.4.6.1. Participant's Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. Boehringer Ingelheim International GmbH
- 8.4.7.1. Participant's Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. Pfizer, Inc.
- 8.4.8.1. Participant's Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. Johnson & Johnson Services, Inc.
- 8.4.9.1. Participant's Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. Otsuka Pharmaceutical Co., Ltd.
- 8.4.10.1. Participant's Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Product Benchmarking
- 8.4.10.4. Recent Developments/ Strategic Initiatives
- 8.4.11. Eli Lilly and Company
- 8.4.11.1. Participant's Overview
- 8.4.11.2. Financial Performance
- 8.4.11.3. Product Benchmarking
- 8.4.11.4. Recent Developments/ Strategic Initiatives
- 8.4.12. Novo Nordisk A/S
- 8.4.12.1. Participant's Overview
- 8.4.12.2. Financial Performance
- 8.4.12.3. Product Benchmarking
- 8.4.12.4. Recent Developments/ Strategic Initiatives
- 8.4.1. Bayer AG
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.